The Key to a Winning 401(k)
Retirement saving requires key decisions: when to start, how much to save, and where to invest. The investing…
CREATE Medicines Announces Positive First-in-Human Results for MT-302
Data demonstrates proof -of-mechanism for In Vivo CAR therapy in solid tumors CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/…
Blue Origin to launch giant New Glenn rocket again. How to watch
On the eve of the scheduled launch window opening up, here’s how to watch a livestream as the…
Denmark eyes new law to protect citizens from AI deepfakes
COPENHAGEN, Denmark (AP) — In 2021, Danish video game live-streamer Marie Watson received an image of herself from…
Gemini AI to transform Google Maps into a more conversational experience
Google Maps is heading in a new direction with artificial intelligence sitting in the passenger’s seat. Fueled by…
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal
Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a…
Microsoft enters approximately $9.7B contract with IREN that gives it access to Nvidia chips
Microsoft has entered into a $9.7 billion cloud services contract with artificial intelligence cloud service provider IREN that…
FDA’s top drug regulator resigns after federal officials probe ‘serious concerns’
WASHINGTON (AP) — The head of the Food and Drug Administration’s drug center abruptly resigned Sunday after federal…
Lee Soo Man: How the ‘King of K-pop’ built a global industry
SEOUL, South Korea (AP) — Lee Soo Man resisted the title at first. “King of K-pop” sounded too…
How to survive financially after a lay off
How to survive a layoff and protect your finances As more Americans are losing their jobs, these tips…
Which AI Cloud Stock Has More Room to Run?
Nebius Group N.V. NBIS and Amazon.com, Inc. AMZN are major players in the rapidly expanding AI cloud infrastructure…
FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi’s 15-Year Campaign to Cut Biologic Drug Costs
A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi’s Vision to Make Biologics as Affordable as Generics CHICAGO,…